Why is Krebs Biochem falling/rising?

As of 21-Jul, Krebs Biochemicals & Industries Ltd is experiencing a slight increase in its stock price, currently at 82.49, with a change of 0.28 (0.34%) upward. Despite this minor uptick, the stock has shown a mixed performance in recent periods, with a 1-week return of +1.21%, which outperformed the Sensex's +0.03%. However, over the longer term, the stock has underperformed significantly, with a 1-month return of -6.13% and a year-to-date decline of -11.29%. The stock's performance today is notable as it outperformed its sector by 0.66%. Nevertheless, there are concerning signs, such as a significant drop in delivery volume by 75.86% against the 5-day average, indicating falling investor participation. Additionally, the company has a negative book value and has reported negative results for the last two consecutive quarters, which raises concerns about its long-term fundamental strength.
In the broader market context, while Krebs Biochemicals has shown some short-term resilience, it has significantly lagged behind the benchmark, with a 1-year return of -25.60% compared to the Sensex's +2.28%. This stark contrast highlights the stock's struggles in a generally positive market environment. The company's high debt levels and poor growth metrics further exacerbate its challenges, making it a risky investment. The overall market has generated positive returns, yet Krebs Biochemicals continues to face headwinds, leading to its classification as a strong sell due to its weak long-term fundamentals and negative EBITDA.